Adjusted HRs of minor amputations for people with type 1 diabetes vs controls and 95% CIs for time-updated mean HbA1c categories and coexisting normoalbuminuria and eGFR >60 mL/min
| Amputation below ankle | HR (95% CI), p value | |||
| Diabetes duration 30years | Diabetes duration 40years | Diabetes duration 50years | Diabetes duration 60years | |
| Time-updated mean HbA1c categories and albuminuria | ||||
| Controls (reference) | 1.00 | 1.00 | 1.00 | 1.00 |
| ≤52 mmol/mol (≤6.9%)—normoalbuminuria | 11.3 (5.2 to 24.6)* | 12.5 (5.8 to 27.2)* | 13.9 (6.3 to 30.5)* | 15.4 (6.8 to 34.6)* |
| 53–62 mmol/mol (7.0%–7.8%)—normoalbuminuria | 34.9 (22.2 to 54.9)* | 38.7 (24.8 to 60.4)* | 43.0 (27.1 to 68.1)* | 47.6 (29.0 to 78.3)* |
| 63–72 mmol/mol (7.9%–8.7%)—normoalbuminuria | 49.6 (32.2 to 76.5)* | 55.0 (35.9 to 84.2)* | 61.0 (39.2 to 95.1)* | 67.7 (41.7 to 109.7)* |
| 73–82 mmol/mol (8.8%–9.6%)—normoalbuminuria | 61.8 (37.2 to 102.6)* | 68.5 (41.5 to 113.1)* | 76.0 (45.3 to 127.5)* | 84.3 (48.6 to 146.3)* |
| ≥83 mmol/mol (≥9.7%)—normoalbuminuria | 221.8 (134.0 to 367.0)* | 245.8 (149.0 to 405.3)* | 272.8 (162.5 to 457.8)* | 302.4 (173.8 to 526.3)* |
| ≤52 mmol/mol (≤6.9%)—not normoalbuminuria | 87.9 (48.9 to 157.9)* | 97.4 (54.8 to 173.0)* | 108.1 (60.4 to 193.4)* | 119.9 (65.4 to 219.7)* |
| 53–62 mmol/mol (7.0%–7.8%)—not normoalbuminuria | 91.7 (58.0 to 144.9)* | 101.6 (65.2 to 158.2)* | 112.7 (71.7 to 177.2)* | 125.0 (77.1 to 202.7)* |
| 63–72 mmol/mol (7.9%–8.7%)—not normoalbuminuria | 139.2 (91.5 to 211.5)* | 154.2 (102.7 to 231.5)* | 171.1 (112.5 to 260.4)* | 189.8 (120.2 to 299.5)* |
| 73–82 mmol/mol (8.8%–9.6%)—not normoalbuminuria | 252.0 (166.4 to 381.5)* | 279.2 (186.4 to 418.2)* | 309.9 (203.8 to 471.4)* | 343.6 (217.4 to 543.1)* |
| ≥83 mmol/mol (≥9.7%)—not normoalbuminuria | 547.9 (359.9 to 834.1)* | 607.1 (402.6 to 915.6)* | 673.8 (439.6 to 1032.8)* | 747.1 (468.9 to 1190.4)* |
| Time-updated mean HbA1c categories and eGFR | ||||
| ≤52 mmol/mol (≤6.9%)—eGFR ≥60 | 14.7 (7.4 to 29.4)* | 16.0 (8.0 to 31.8)* | 17.3 (8.6 to 34.9)* | 18.8 (9.1 to 38.9)* |
| 53–62 mmol/mol (7.0%–7.8%)—eGFR ≥60 | 34.7 (22.2 to 54.1)* | 37.6 (24.3 to 58.3)* | 40.9 (26.0 to 64.3)* | 44.4 (27.2 to 72.5)* |
| 63–72 mmol/mol (7.9%–8.7%)—eGFR ≥60 | 55.7 (36.7 to 84.4)* | 60.5 (40.2 to 90.9)* | 65.6 (42.8 to 100.5)* | 71.2 (44.6 to 113.8)* |
| 73–82 mmol/mol (8.8%–9.6%)—eGFR ≥60 | 98.1 (63.6 to 151.3)* | 106.5 (69.5 to 163.2)* | 115.6 (74.0 to 180.5)* | 125.5 (77.2 to 204.1)* |
| ≥83 mmol/mol (≥9.7%)—eGFR ≥60 | 297.7 (191.8 to 462.2)* | 323.2 (209.0 to 499.8)* | 350.8 (222.3 to 553.6)* | 380.9 (231.5 to 626.6)* |
| ≤52 mmol/mol (≤6.9%)—eGFR <60 | 91.1 (48.4 to 171.6)* | 98.9 (53.1 to 184.2)* | 107.4 (57.3 to 201.1)* | 116.6 (60.8 to 223.4)* |
| 53–62 mmol/mol (7.0%–7.8%)—eGFR <60 | 117.3 (73.0 to 188.5)* | 127.3 (80.4 to 201.6)* | 138.2 (86.5 to 220.8)* | 150.0 (91.1 to 247.1)* |
| 63–72 mmol/mol (7.9%–8.7%)—eGFR <60 | 178.2 (114.6 to 276.9)* | 193.4 (126.0 to 296.8)* | 209.9 (135.2 to 326.0)* | 227.9 (141.7 to 366.5)* |
| 73–82 mmol/mol (8.8%–9.6%)—eGFR <60 | 299.9 (191.0 to 471.0)* | 325.6 (209.9 to 505.0)* | 353.4 (225.2 to 554.7)* | 383.7 (236.2 to 623.3)* |
| ≥83 mmol/mol (≥9.7%)—eGFR <60 | 693.3 (442.0 to 1087.5)* | 752.6 (485.0 to 1167.8)* | 816.9 (519.4 to 1284.8)* | 886.9 (544.1 to 1445.5)* |
Adjusted for time-updated age, sex, born in Sweden, maximum educational level, baseline comorbidities and time-updated diabetes duration centered at 30, 40, 50 and 60 years.
*Significant at p<0.0001.